Under the agreement, Oxford will establish a presence in the U.S. and will offer global pharmaceutical and biotechnology clients manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford will provide access to Homology's end-to-end manufacturing capabilities.

Oxford said it will incorporate 125 AAV manufacturing experts, an experienced team, high-quality good manufacturing practices (GMP) vector production capabilities, over 40 developed analytical assays, and an established breadth of vector characterization in a GMP facility near Boston.

The new business will pay Homology $130 million upfront and invest $50 million to fund Oxford Biomedica Solutions. Oxford will have an 80% ownership stake in the new company, and Homology will own 20%. The transaction is expected to close in the first quarter of 2022, subject to the satisfaction of certain closing conditions, including requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Oxford Biomedica to manufacture vectors for Boehringer Ingelheim
Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.